Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Melanoma|Triple-Negative Breast Cancer
Interventions: BIOLOGICAL: Imprime PGG|DRUG: Pembrolizumab
Sponsor: HiberCell, Inc.
Collaborators: Merck Sharp & Dohme LLC